Special Issue

Exosomes as Drug Carriers for Cancer Therapy

Message from the Guest Editors

Liquid biopsy has several advantages over conventional methods, as it is less invasive, easily obtainable, repeatable, less burdensome for the patient, and more applicable in the diagnosis of distinct diseases. Early detection, characterization, and monitoring of cancer are possible by using extracellular vesicles (EVs), i.e., mainly exosomes isolated from liquid biopsy samples. Exosomes are packed with several molecules, such as nucleic acids, proteins, lipids, and metabolites. When these are released, they may affect the cell-to-cell communication, contributing to tumorigenesis, angiogenesis, metastasis, signal transduction, and immune responses. Several beneficial properties of exosomes make them promising therapeutic shuttle vesicles. Engineered exosome-based personalized medicine may be a new treatment option for cancer. This Special Issue aims to address the latest research or new views on exosomes in the monitoring. characterization, and understanding of background mechanisms within cancer, as well as possible therapeutic applications for cancer therapy.

Guest Editors

Prof. Dr. Sveva Bollini

Regenerative Medicine Laboratory, Department of Experimental Medicine, University of Genova, 16132 Genova, Italy

Dr. Beáta Soltész

Department of Human Genetics, Faculty of Medicine, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary

Deadline for manuscript submissions

closed (10 November 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/116858

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

